Tirzepatide is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes, working as a dual GLP-1/GIP receptor agonist that targets both the GLP-1 and GIP receptors instead of GLP-1 alone, which enhances fat metabolism and insulin sensitivity beyond a single-receptor peptide
Enter SNAC technology, the pills protective shield or bodyguard
CDI Query Trigger HCC 189 Capture: Any patient with documented history of lower extremity amputation even if seen for an unrelated reason should have their amputation status code (Z89.xxx) captured every encounter year
While taking a GLP-1 medication, you may experience: Constipation Diarrhea Loss of appetite Nausea Vomiting How to manage GLP-1 side effects If youre experiencing health side effects while taking GLP-1 medications, talk to your doctor
The downside of this is that there are no half-doses or slow adjustments, and you get the manufacturers standard treatment
Tirzepatide became the first dual GLP/GLP-1 receptor agonist to gain FDA approval for treating T2DM in 2022 and obesity in 2023 [ Table 2 ]
.png)
